FA
FLNA

Fermata Advisors’s Filana Therapeutics FLNA Stock Holding History

Fermata Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,821
Closed -$211K – 199
2021
Q4 		$211K Sell
4,821
-275
-5% -$14.4K 0.08% 178
2021
Q3 		$316K Buy
5,096
+1,298
+34% +$108K 0.14% 117
2021
Q2 		$325K Buy
+3,798
New +$203K 0.19% 97

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Fermata Advisors's FLNA Position: Q1 2022 in Review

Fermata Advisors sold out of Filana Therapeutics (FLNA) in Q1 2022, closing a stake of 4,821 shares — an estimated $211K sold.

Fermata Advisors first reported a position in FLNA in Q2 2021 and held it in 3 quarters. The position peaked at $325K in Q2 2021. 163 funds tracked by Wall St. Rank hold FLNA as of Q1 2022.

  • Fermata Advisors reported no remaining Filana Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Fermata Advisors sold 4,821 Filana Therapeutics shares in Q1 2022, an estimated $211K.
  • Fermata Advisors first reported a position in Filana Therapeutics in Q2 2021 and held it in 3 quarters.
  • Fermata Advisors's Filana Therapeutics position peaked at $325K in Q2 2021.
  • 163 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2022.

Based on Fermata Advisors's 13F filing for Q1 2022, filed 22 Apr 2022.